Krakow, Poland – 02 October – Selvita will participate and present at the upcoming 18th Annual Biotech in Europe Forum, which will take place 4 – 5 October 2018 in Basel, Switzerland. The conference is organized by Sachs Associates.
Selvita is scheduled to present a corporate overview at 14:15 on Thursday, October 4, 2018, in the Room Darwin during Track C, at the Congress Center Basel, with one-on-one meetings held throughout the two days.
Magdalena Marciniak, Business Alliance Manager, will provide a corporate and scientific overview of the Company’s current activities, focusing on the most recent developments of its R&D oncology pipeline, strategic discovery collaborations and plans for the further corporate development.
The Annual Biotech in Europe Forum is one of the leading international conferences for professionals interested in investing and partnering in the biotech and life science industry. The event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers, and pharma licensing executives. Over 650 delegates and over 100 presenting companies and 20+ pitches by seed companies are expected to attend. The program will feature twelve plenary panels and workshops covering BD & Licensing in the main therapeutic areas.
To connect Selvita’s delegates at this conference, please contact us at: email@example.com, or +48 539 939 584
To find more about the forum:
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
+48 660 797 362